Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.

Researchers have discovered and analysed a rare but serious side effect of an innovative form of blood cancer therapy.

Also, regarding HyBryte (TM), in October 2024, Soligenix announced that the Hong Kong Patent Office had granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin." Synthetic ...

Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma ... as well as multiple early-stage programs ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...

Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary ...

TuHURA Biosciences, a biotech firm, is advancing DNA-based immunotherapy for cancer. Read what warrants a Hold rating for ...